Literature DB >> 26342593

Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism.

Laura Gigante1, Irene Paganini2, Marina Frontali3, Serena Ciabattoni2, Federica Carla Sangiuolo4, Laura Papi2.   

Abstract

Rhabdoid tumors are aggressive malignancies that show loss-of-function mutations of SMARCB1 gene, a member of the SWI/SNF chromatin-remodeling complex controlling gene transcription. One-third of patients affected by rhabdoid tumor harbor a germ-line mutation of SMARCB1 defining a rhabdoid tumor predisposition syndrome. The occurrence of a second somatic mutation determines the development of neoplasia in a two-hit model. Most germ-line mutations occur de novo, and few cases of recurrence in a sibship have been described. Here we report on a new Italian family with recurrence of SMARCB1 germ-line deletion in two siblings due to gonadal mosaicism. The deletion was identified in the 9-month-old proband with malignant rhabdoid tumor of the right kidney and disseminated metastases. Testing of both parents confirmed the de novo origin of the mutation, but recurrence was then detected prenatally in a new pregnancy. This is the sixth family with malignant rhabdoid tumor predisposition syndrome with the recurrence of the same germ-line SMARCB1 mutation in the sibship but not in healthy parents, suggesting that gonadal mosaicism is a less rare event than supposed. The clinical outcome in our patient confirms previous data of poorer outcome in patients with rhabdoid tumor predisposition syndrome.

Entities:  

Keywords:  22q deletion; Gonadal mosaicism; Prenatal diagnosis; Rhabdoid tumor; SMARCB1

Mesh:

Substances:

Year:  2016        PMID: 26342593     DOI: 10.1007/s10689-015-9836-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  10 in total

1.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.

Authors:  J A Biegel; J Y Zhou; L B Rorke; C Stenstrom; L M Wainwright; B Fogelgren
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

2.  Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS).

Authors:  Uwe Kordes; Kerstin Bartelheim; Piergiorgio Modena; Maura Massimino; Veronica Biassoni; Harald Reinhard; Martin Hasselblatt; Reinhard Schneppenheim; Michael C Frühwald
Journal:  Pediatr Blood Cancer       Date:  2013-10-03       Impact factor: 3.167

3.  Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor.

Authors:  Franck Bourdeaut; Delphine Lequin; Laurence Brugières; Stéphanie Reynaud; Christelle Dufour; François Doz; Nicolas André; Jean-Louis Stephan; Yves Pérel; Odile Oberlin; Daniel Orbach; Christophe Bergeron; Xavier Rialland; Paul Fréneaux; Dominique Ranchere; Dominique Figarella-Branger; Georges Audry; Stéphanie Puget; D Gareth Evans; Joan Carles Ferreres Pinas; Valeria Capra; Véronique Mosseri; Isabelle Coupier; Marion Gauthier-Villars; Gaëlle Pierron; Olivier Delattre
Journal:  Clin Cancer Res       Date:  2011-01-01       Impact factor: 12.531

4.  hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.

Authors:  M F Rousseau-Merck; I Versteege; I Legrand; J Couturier; A Mairal; O Delattre; A Aurias
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

5.  Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system.

Authors:  Carol S Bruggers; Steven B Bleyl; Theodore Pysher; Philip Barnette; Zeinab Afify; Marion Walker; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2010-09-16       Impact factor: 3.167

6.  Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers.

Authors:  N Sévenet; E Sheridan; D Amram; P Schneider; R Handgretinger; O Delattre
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

7.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors.

Authors:  Katherine W Eaton; Laura S Tooke; Luanne M Wainwright; Alexander R Judkins; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

8.  Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor.

Authors:  Uwe Kordes; Stefan Gesk; Michael Christoph Frühwald; Norbert Graf; Ivo Leuschner; Martin Hasselblatt; Astrid Jeibmann; Florian Oyen; Ove Peters; Torsten Pietsch; Reiner Siebert; Reinhard Schneppenheim
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

9.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

Review 10.  The role of SMARCB1/INI1 in development of rhabdoid tumor.

Authors:  Charles W M Roberts; Jaclyn A Biegel
Journal:  Cancer Biol Ther       Date:  2009-03-29       Impact factor: 4.742

  10 in total
  6 in total

Review 1.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

Review 2.  The 22q11.2 Microdeletion in Pediatric Patients with Cleft Lip, Palate, or Both and Congenital Heart Disease: A Systematic Review.

Authors:  Diana Cárdenas-Nieto; Maribel Forero-Castro; Clara Esteban-Pérez; Julio Martínez-Lozano; Ignacio Briceño-Balcázar
Journal:  J Pediatr Genet       Date:  2019-10-23

Review 3.  The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.

Authors:  Hildegard Kehrer-Sawatzki; Said Farschtschi; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2016-12-05       Impact factor: 4.132

4.  Co-occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1.

Authors:  Hildegard Kehrer-Sawatzki; Uwe Kordes; Simone Seiffert; Anna Summerer; Christian Hagel; Ulrich Schüller; Said Farschtschi; Reinhard Schneppenheim; Martin Bendszus; Tim Godel; Victor-Felix Mautner
Journal:  Mol Genet Genomic Med       Date:  2018-05-20       Impact factor: 2.183

5.  The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.

Authors:  Xinke Xu; Hongyao Yuan; Junping Pan; Wei Chen; Cheng Chen; Yang Li; Fangcheng Li
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

6.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.